The objective is to investigate the treatment of non-anemic iron deficiency (NAID) and the impact on development of anemia later in pregnancy. Anemia in the third trimester has been identified as a risk factor for maternal and fetal morbidity that might lead to mortality. Due to the high incidence of NAID in pregnancy, there is an opportunity for early screening and treatment to decrease progression to anemia. The primary aim of this study is to establish if treatment of NAID will result in higher third trimester hemoglobin values and decrease incidence of anemia at term.

Start Date12 Aug 2022

Sponsor / Collaborator

Stony Brook University

NCT04930237 / WithdrawnNot ApplicableIIT

RELISTOR's Effects on Opioid-Induced Constipation in Postoperative 1-2 Level Anterior Lumbar Interbody Fusion Patients: A Case-Control Study

This will be a prospective case-control study of 40 patients undergoing 1-2 level ALIF procedures at Methodist Dallas Medical Center (MDMC). Patient records will be reviewed to identify details including demographics, comorbidities, procedure details, and the primary and secondary outcome metrics.

Start Date01 Jul 2021

Sponsor / Collaborator

Methodist Health System, Inc.

100 Clinical Results associated with Dioctyl Sodium Sulfosuccinate

100 Translational Medicine associated with Dioctyl Sodium Sulfosuccinate

100 Patents (Medical) associated with Dioctyl Sodium Sulfosuccinate

5,338

Literatures (Medical) associated with Dioctyl Sodium Sulfosuccinate

01 Jun 2025·BIOELECTROCHEMISTRY

Effect of preferential growth of Shewanella oneidensis MR-1 on microbial corrosion of constituent phases of 2205 duplex stainless steel

Article

Author: Wang, Wenkai ; Wu, Jiajia ; Arroussi, Mohammed ; Zhu, Liyang ; Wang, Peng ; Zhang, Dun

Understanding selective growth of electroactive bacteria on surface of constituent phases (ferrite/ austenite) of 2205 DSS is required for mitigating microbiologically influenced corrosion (MIC). In this study, the preferential attachment of bacteria and its impact on corrosion of single phase were investigated under anaerobic condition using Shewanella oneidensis MR-1. Single-ferrite phase was more susceptible to biofilm formation compared with single-austenite phase. Atomic force microscope (AFM) revealed that the surface of ferrite phase coupon was fully covered with S. oneidensis MR-1 biofilm whereas few S. oneidensis MR-1 cells were observed on the surface of austenite phase. After 14 d of incubation, the maximum biofilm thicknesses on 2205 DSS, ferrite and austenite phase were 15.5 ± 1.0 µm, 13.8 ± 3.2 µm, and 10.2 ± 0.8 µm, respectively. S. oneidensis MR-1 accelerated the pitting corrosion of materials. The maximum pits depth on single ferrite and austenite phase in sterile medium (3.2 µm vs 2.2 µm with mean values 2.5 µm vs 1.7 µm) were relatively small than those in biotic medium (6.0 µm vs 4.5 µm with mean values 4.5 µm vs 3.8 µm). Synergistic effects of Cr and Ni enhanced the stability of passive film on austenite phase.

15 Feb 2025·INTERNATIONAL JOURNAL OF CANCER

Ninjurin1 deficiency differentially mitigates colorectal cancer induced by azoxymethane and dextran sulfate sodium in male and female mice

Article

Author: Kim, Nayoung ; Kim, Kyu‐Won ; Seok, Yeong‐Jae ; Ha, Sungchan ; Oh, Goo Taeg ; Song, Chin‐Hee ; Choi, Soo In ; Choi, Hoon ; Jeon, Sejin ; Kim, Eun Hye ; Shin, Eun ; Nam, Ryoung Hee ; Jang, Jae Young

Abstract:

This study investigated the role of Ninjurin1 (Ninj1), encoding a small transmembrane protein, in colitis‐associated colon tumorigenesis in relation to sex hormones. Male and female wild‐type (WT) and Ninj1 knockout (KO) mice were treated with azoxymethane (AOM) and dextran sulfate sodium (DSS), with or without testosterone propionate (TP). At week 2 (acute colitis stage), Ninj1 KO exhibited an alleviation in the colitis symptoms in both male and female mice. The M2 macrophage population increased and CD8+ T cell population decreased only in the female Ninj1 KO than in the female WT AOM/DSS group. In the female AOM/DSS group, TP treatment exacerbated colon shortening in the Ninj1 KO than in the WT. At week 13 (tumorigenesis stage), male Ninj1 KO mice had fewer tumors, but females showed similar tumors. In the WT AOM/DSS group, females had more M2 macrophages and fewer M1 macrophages than males, but this difference was absent in Ninj1 KO mice. In the Ninj1 KO versus WT group, the expression of pro‐inflammatory mediators and Ho‐1 and CD8+ T cell populations decreased in both female and male Ninj1 KO mice. In the WT group, M2 macrophage populations were increased by AOM/DSS treatment and decreased by TP treatment. However, neither treatment changed the cell populations in the Ninj1 KO group. These results suggest that Ninj1 is involved in colorectal cancer development in a testosterone‐dependent manner, which was different in male and female. This highlights the importance of considering sex disparities in understanding Ninj1's role in cancer pathogenesis.

01 Feb 2025·Journal of Proteomics

Probiotic Bacillus cereus regulates metabolic disorders and activates the cholic acid-FXR axis to alleviate DSS-induced colitis

Article

Author: Wu, Shihui ; Zhou, Guixian ; Mei, Shihui ; Yang, Ying ; Ou, Bingmin ; Wen, Guilan ; Liao, Yixiao ; Wen, Ming

Inflammatory bowel disease is characterized by severe imbalance of intestinal flora and metabolic disorders. Recent studies have demonstrated that probiotics can effectively alleviate inflammatory bowel disease by restoring the intestinal flora structure and modulating the immune response. However, the role of probiotics in regulating intestinal metabolism disorders is still unclear. This study explores the role of probiotic B. cereus in alleviating DSS-induced colitis. The findings indicated probiotic B. cereus treatment mitigated tissue damage and apoptosis during inflammation. Metabolome and transcriptome analysis revealed B. cereus activated the cholic acid-FXR axis by increasing cholic acid levels, which promoted the gene expression level of NF-κB inhibitor α, reduced the IL-1β, IL-6, IL-18 and TNF-α concentrations. Furthermore, it effectively mitigated the DSS-induced disruption of bile acid metabolism, arginine metabolism, and linoleic acid metabolism. This study explores the effect and mechanisms of probiotic B. cereus on alleviating DSS-induced colitis. It aims to provide a theoretical basis for microbial therapy in inflammatory bowel disease. SIGNIFICANCE: This study used metabolome and transcriptome to reveal the roles and mechanisms, which probiotic Bacillus cereus modulates metabolic disorders and alleviate DSS-induced colitis. We identified the cholic acid-FXR axis as an important target for alleviating DSS-induced colitis. These findings provide new insights into microbial treatment strategies for IBD.

News (Medical) associated with Dioctyl Sodium Sulfosuccinate

21 May 2024

·www.biospace.com

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models

Data presented at Digestive Disease Week (DDW) 2024 Preclinical data demonstrate PALI-2108 to be safe, effective, and well tolerated PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure PALI-2108 exhibited a dose-dependent efficacy response in two DSS colitis mouse models, achieving efficacy comparable to doses of apremilast considered intolerable for human use in Ulcerative Colitis (UC) patients Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of UC before year end Carlsbad, CA, May 21, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the presentation of positive preclinical data from PALI-2108, an orally administered, locally acting colon-specific Phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC, at DDW 2024 being held in Washington, D.C., May 18-21, 2024. The poster titled, “Local Bioactivation and efficacy of PALI-2108: A Promising PDE4 Inhibitor Prodrug for Ulcerative Colitis Treatment,” is being presented by Dr. Mitch Jones as part of the Animal Models of IBD: Pre-Clinical Treatment of Intestinal Inflammation session being held today, May 21, 2024. The poster is available on the Scientific Publications page of the Company’s website. “The findings from this preclinical study add to our growing body of encouraging data for PALI-2108 and further bolster our confidence in its potential in the treatment of UC,” commented Dr. Mitch Jones, CMO of Palisade Bio. “Based on the data demonstrated to date, we believe PALI-2108 has the potential to be the first approved PDE4 inhibitor for UC and importantly, provide a much-needed solution for patients.” The preclinical data highlighted in the poster reveal significant advancements in assessing on-target PDE4 binding within colon tissue homogenates when dosed with apremilast, PALI-2108, or Vehicle, utilizing a classic cellular thermal shift assay (CETSA) to detect changes in thermal stability. To comprehensively evaluate PALI-2108's efficacy across various doses, researchers employed an acute colitis model in mice induced by 4% DSS in drinking water from Day 1 to Day 8. Mice received twice-daily (BID) treatments of PALI-2108 at 20, 40, and 80 mg/kg/dose BID, while cyclosporin A and apremilast were administered at 40 and 12.5 mg/kg/dose BID, respectively. The assessment of DSS-induced colitis included monitoring Body Weight score, Stool Consistency score, and Fecal Blood score from Day 1 to Day 8, with evaluations conducted 1 to 2 hours post-dosing. Overall disease state was measured using a Disease Activity Index (DAI) score, calculated by pooling the three in-life scores, assessed daily from Days 1 to 8. Furthermore, a single oral dose of the prodrug PALI-2108 at 43 mg/kg and active PALI-0008 at 0.1, 0.3, 1, and 3 mg/kg was administered to dogs, with a focus on monitoring key clinical adverse events, including emesis. Remarkably, the PALI-2108 prodrug prevented emesis observed with lower doses of the PDE4 active moiety in the model, demonstrating an enhanced therapeutic window. Key Findings PALI-2108 demonstrates similar target engagement to the PDE4 inhibitor, apremilast, which is approved for use in psoriasis and psoriatic arthritis. In a DSS colitis mouse model, PALI-2108 significantly prevented colon length reduction in dose dependent manner, and showed dose dependent improvements in body weight score, stool consistency score, fecal blood score, overall disease activity index (DAI) score, and AUC of DAI over the course of the study. Importantly, PALI-2108 exhibited a dose-dependent efficacy response in two DSS colitis mouse models, achieving efficacy comparable to doses of apremilast considered intolerable for human use in UC patients. No systemic toxicity in dogs and large therapeutic window due to local activation. About Palisade Bio Palisade Bio is a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to . Forward Looking Statements This communication contains “forward-looking” statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the extent of our cash runway; our ability to successfully develop our licensed technologies; estimates about the size and growth potential of the markets for our product candidates, and our ability to serve those markets, including any potential revenue generated; future regulatory, judicial, and legislative changes or developments in the United States (U.S.) and foreign countries and the impact of these changes; our ability to maintain the Nasdaq listing of our securities; our ability to build a commercial infrastructure in the U.S. and other markets; our ability to compete effectively in a competitive industry; our ability to identify and qualify manufacturers to provide API and manufacture drug product; our ability to enter into commercial supply agreements; the success of competing technologies that are or may become available; our ability to attract and retain key scientific or management personnel; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; our ability to obtain funding for our operations; our ability to attract collaborators and strategic partnerships; and the impact of the COVID-19 pandemic or any global event on our business, and operations, and supply. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon the Company’s current expectations. Forward-looking statements involve risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the Company’s ability to advance its nonclinical and clinical programs, the uncertain and time-consuming regulatory approval process; and the Company’s ability to secure additional financing to fund future operations and development of its product candidates. Additional risks and uncertainties can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2024. These forward-looking statements speak only as of the date hereof and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. Investor Relations Contact JTC Team, LLC Jenene Thomas 833-475-8247 PALI@jtcir.com Source: Palisade Bio

Clinical ResultPhase 1

22 May 2023

·www.sciencedaily.com

Study may explain why high-sugar diets can worsen IBD

Excess sugar hampers cells that renew the colon's lining in a mouse model of inflammatory bowel disease (IBD), according to a new study that could help get to the bottom of why limiting sugary foods can ease symptoms for patients with IBD. Excess sugar hampers cells that renew the colon's lining in a mouse model of inflammatory bowel disease (IBD), according to a new study by University of Pittsburgh scientists. The findings, published in Cellular and Molecular Gastroenterology and Hepatology, could help get to the bottom of why limiting sugary foods can ease symptoms for patients with IBD. "The prevalence of IBD is rising around the world, and it's rising the fastest in cultures with industrialized, urban lifestyles, which typically have diets high in sugar," said senior author Timothy Hand, Ph.D., associate professor of pediatrics and immunology at Pitt's School of Medicine and UPMC Children's Hospital of Pittsburgh. "Too much sugar isn't good for a variety of reasons, and our study adds to that evidence by showing how sugar may be harmful to the gut. For patients with IBD, high-density sugar -- found in things like soda and candy -- might be something to stay away from." Led by Ansen Burr, Ph.D., a student in Pitt's Medical Scientist Training Program, the researchers started by feeding mice either a standard or high-sugar diet. Then they mimicked symptoms of IBD by treating the animals with a chemical called DSS that causes damage to the colon. To their shock, all the mice on the high-sugar diet died within nine days. In contrast, all the animals on the standard diet survived until the end of the 14-day experiment. To learn what made sugar so deadly in mice with IBD symptoms, the team looked at the animals' colons. Also known as the large intestine, the colon is lined with a layer of epithelial cells that are arranged in finger-like projections called crypts. In a healthy colon, these cells are continually replenished by dividing stem cells at the bottom of each crypt. "The colon epithelium is like a conveyor belt," said Hand, who is also director of Pitt's Gnotobiotic Animal Core Laboratory. "It takes five days for cells to travel through the circuit from the bottom to the top of the crypt, where they are shed into the colon and defecated out. You essentially make a whole new colon every five days." When mice on the high-sugar diet were given DSS, that circuit collapsed, said Hand. In some of the animals, the protective layer of epithelial cells was completely lost, causing the colon to be full of blood and immune cells. Unexpectedly, a high-sugar diet was similarly lethal in germ-free mice treated with DSS, showing that sugar affects the colon directly and is not dependent on the gut microbiome as the researchers had predicted. Next, the team tested how sugar affected mouse and human colonoids, poppy seed-sized miniature intestines that can be grown in a lab dish. As concentrations of glucose, sucrose or fructose increased, fewer colonoids developed and they grew slower, evidence that sugar impaired cell division. "We found that stem cells were dividing much more slowly in the presence of sugar -- likely too slow to repair damage to the colon," said Hand. "The other strange thing we noticed was that the metabolism of the cells was different. These cells usually prefer to use fatty acids, but after being grown in high-sugar conditions, they seemed to get locked into using sugar." In sugary conditions, the cells had vastly altered metabolic pathways, and they produced lower levels of ATP, the energy-providing molecule that drives cellular processes. The researchers suspect that this rewiring of cellular pathways inhibits the capacity of stem cells to divide, slowing renewal of the colon lining and accelerating gut damage in IBD. According to Hand, these findings could help explain other research that has linked sweetened beverages, including sodas, soft drinks and juices, to negative outcomes in IBD patients. "If you eat an apple or an orange, you're eating a lot of sugar, but that sugar is tied up in the fruit's cells, so it takes a long time to digest and open up those cells to get the sugar," said Hand. "Whereas if you drink a soda, the sugar is available almost the second it hits your intestine, and it's easy to drink a huge amount of sugar in a very short time. Our research suggests that consuming high levels of sugar could have negative outcomes for repairing the colon in patients with inflammatory bowel disease." Hand said that future research, done in in collaboration with coauthor Semir Beyaz, Ph.D., assistant professor at Cold Spring Harbor Laboratory, will focus on understanding how diet and immune response can affect IBD. "I think that we need to investigate more deeply what diets are going to benefit patients who have intestinal damage, whether that be from IBD or from radiation therapy to treat colon cancer," said Hand. "It's about a nutraceutical approach to colon damage, or the idea of finding the right diet for a particular patient." Other authors on the study were Junyi Ji, B.Med., of Tsinghua University; Kadir Ozler, B.S., Onur Eskiocak, B.S., and Brian Yueh, B.S., of Cold Spring Harbor Laboratory; and Heather L. Mentrup, Ph.D., Rachel Cumberland, B.A., Ashley V. Menk, B.S., Natalie Rittenhouse, B.S., Chris W. Marshall, Ph.D., Pailin Chiaranunt, B.S., Xiaoyi Zhang, M.D., Ph.D., Lauren Mullinax, M.D., Abigail Overacre-Delgoffe, Ph.D., Vaughn S. Cooper, Ph.D., Amanda C. Poholek, Ph.D., Greg M. Delgoffe, Ph.D., and Kevin P. Mollen, M.D., all of Pitt or UPMC. This work was supported by the Richard King Mellon Institute for Pediatric Research, the National Institutes of Health (T32AI089443-10), the Damon Runyon Cancer Research Foundation (2360-19), the Kenneth Rainin Foundation and the Cancer Center Support Grant (5P30CA045508).

14 Oct 2021

·www.biospace.com

Avrio Health L.P. Announces Publication of In Vitro Test Results Assessing Betadine® Formulations Against Four Coronaviruses

Betadine® antiseptic products have not been demonstrated to be effective against infections caused by SARS-CoV-2 or any other viruses in vivo, nor have any clinical studies been conducted to assess its safety or effectiveness as a virucidal agent. Betadine Topical Antiseptic products currently available in the U.S. are for external use only and should not be gargled or swallowed. Use only as directed on the label. Betadine Sore Throat Gargle (0.5% povidone-iodine antiseptic gargle), which should not be ingested, is used for the temporary relief of sore throat. STAMFORD, Conn.--(BUSINESS WIRE)-- Avrio Health L.P. today announced the publication of results from two in vitro laboratory studies assessing Betadine® antiseptic products (active ingredient: povidone-iodine or “PVP-I”) against four coronaviruses used as a surrogate for SARS-CoV-2. The studies, published in Infectious Diseases and Therapy, found that Betadine Topical Solution, Betadine Surgical Scrub, and Betadine Gargle demonstrated virucidal activity against the coronaviruses studied. “While further data are needed, publication of these studies helps advance the knowledge of PVP-I’s potential virucidal properties,” said Julie Ducharme, BPharm, MSc, PhD, vice president and chief scientific officer. “Avrio Health is committed to scientific exploration to help inform health care provider response to public health needs.” This in vitro research evaluated Betadine Topical Solution, Betadine Surgical Scrub, and Betadine Gargle against four coronaviruses used as surrogates to the SARS-CoV-2 virus: Murine Hepatitis Virus Strain A59, a betacoronavirus within the subfamily Coronavirinae-2; as well as human coronavirus strains OC43 (alphacoronavirus), NL63 (alphacoronavirus) and 229E (betacoronavirus) in a second study. These two studies were conducted under ASTM E-1052-11 methods for measuring virucidal time kill to assess the activity of microbicides against viruses. Betadine Topical Solution (containing 5.0% and 10.0% PVP-I), Betadine Surgical Scrub (containing 7.5% PVP-I), and Betadine Gargle (containing 0.5% PVP-I) were compared to placebo in two separate in vitro studies and showed virucidal activity against four coronaviruses. Betadine Topical Solutions and Gargle showed a 99.99 percent (≥ 4 log) reduction of viral load against one or more strains starting at 15 seconds and at all subsequent time points (30 seconds, 60 seconds and 5 minutes). Results for Betadine Surgical Scrub showed a 99.9 percent (≥ 3 log) reduction across all strains in both studies starting at 15 seconds and at all other time points.1 “These two studies are part of a research project assessing the safety and effectiveness of Betadine antiseptic products against coronaviruses. While the in vitro nature of the study design prevents clinical interpretation of the findings and further investigations are needed to evaluate SARS-CoV-2 inactivation, this work builds on the current body of knowledge intended to advance the science,” said Craig Landau, MD, president and CEO, Purdue Pharma. These two studies were funded by Imbrium Therapeutics L.P., in collaboration with Avrio Health. About Betadine® Betadine® Topical Antiseptic products have been used in the hospital and outpatient setting for their antimicrobial properties for more than 50 years. Betadine® Topical Antiseptic products currently available in the U.S. are for external use only and should not be gargled or swallowed. Use only as directed on the label. Betadine® Sore Throat Gargle (0.5% povidone-iodine antiseptic gargle), which should not be ingested, is used for the temporary relief of sore throat. About Avrio Health L.P. Avrio Health L.P. is a consumer health products company that champions an improved quality of life for people in the United States through the reimagining of innovative product solutions. We have a strong portfolio of well-respected and proven effective brands, including Betadine®, Colace®, Senokot®, and SlowMag® Mg. 1. Shet, M., Hong, R., Igo, D. et al. In Vitro Evaluation of the Virucidal Activity of Different Povidone–Iodine Formulations Against Murine and Human Coronaviruses. Infect Dis Ther (2021).

100 Deals associated with Dioctyl Sodium Sulfosuccinate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Dioctyl Sodium Sulfosuccinate	A06AA02	DB11089

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Constipation	-	-	-
Hemorrhoids	-	-	-
Pharmaceutical aids	-	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Herpes Simplex	Phase 2	US	Meditech Pharmaceuticals, Inc.	-
Acne Vulgaris	Preclinical	US	Meditech Pharmaceuticals, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03523715 (CTgov)	Phase 4	Constipation	77	Prunes+Docusate Sodium (Prunes)	espwkfmasw(ksjjbafdxs) = aqkrwaberk fmoeeiburb (pommxwddyx, hbshwexvqs - ethmuzecjf) View more	-	08 Apr 2021
NCT03523715 (CTgov)	Phase 4	Constipation	77	Docusate Sodium (Control)	espwkfmasw(ksjjbafdxs) = wvpthidvus fmoeeiburb (pommxwddyx, cytbaxddye - xisewcstqm) View more	-	08 Apr 2021
NCT01044212 (CTgov)	Not Applicable	Intestinal Diseases	72	Polyethylene glycol+Dulcolax+Colace	gpdehaptvm(igziedryuy) = glqsndemag bsqdqqbzth (agplofzwne, ycmszmsteu - blglchmywp) View more	-	21 Oct 2015

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis